EUVIMEDEUVIMED entdecken
Crossref

Selective XPO1/CRM1 Inhibitor Verdinexor (KPT-335): The First and Only Oral Treatment Fully Approved by the U.S. FDA for Canine Lymphoma

Zonghui Ma, Zihao Song, Jiakun Zhang, Kaidi Liu, Xiangan Han, José Luis Vaca Roque, Ariel Loza Vega, Wen Zhou

Journal of Medicinal Chemistry · 17.11.2026

DOI: 10.1021/acs.jmedchem.6c03499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 17.11.2026. Verfasst von Zonghui Ma und 7 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Central Public-interest Scientific Institution Basal Research Fund, Chinese Academy of Fishery Sciences.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Central Public-interest Scientific Institution Basal Research Fund, Chinese Academy of Fishery Sciences

Zitieren

APA

Ma, Z., Song, Z., Zhang, J., Liu, K., Han, X., Roque, J. L. V., Vega, A. L., & Zhou, W. (2026). Selective XPO1/CRM1 Inhibitor Verdinexor (KPT-335): The First and Only Oral Treatment Fully Approved by the U.S. FDA for Canine Lymphoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c03499

Vancouver

Ma Z, Song Z, Zhang J, Liu K, Han X, Roque JLV, et al. Selective XPO1/CRM1 Inhibitor Verdinexor (KPT-335): The First and Only Oral Treatment Fully Approved by the U.S. FDA for Canine Lymphoma. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c03499

BibTeX
@article{Ma2026,
  author = {Ma, Zonghui and Song, Zihao and Zhang, Jiakun and Liu, Kaidi and Han, Xiangan and Roque, José Luis Vaca and Vega, Ariel Loza and Zhou, Wen},
  title = {Selective XPO1/CRM1 Inhibitor Verdinexor (KPT-335): The First and Only Oral Treatment Fully Approved by the U.S. FDA for Canine Lymphoma},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c03499}
}
Kostenlos starten →